title: Intensive sequential post-induction therapy for adults with acute myelogenous leukemia in first remission: long-term follow-up and results.
abstract: We designed a post-induction therapy including intensive sequential therapy with non-cross-resistant drugs in an effort to prolong disease-free survival (DFS) for adults with acute myelogenous leukemia. Forty-five patients entered this study and 33 of 35 patients entering complete remission received the post-induction therapy. With a median follow-up for survivors of 3.5 years from complete remission, the actuarial 5-year DFS was 46% +/- 19% (95% confidence interval). The five-year DFS for patients over 45 years of age was comparable to that for patients under 45 years of age (50% +/- 26% vs 47% +/- 28%). Furthermore, the actuarial 5-year DFS for patients who required two courses of induction therapy was comparable to that for patients who required only one course of induction therapy (45% +/- 29% vs 50% +/- 25%). The toxicity of post-induction therapy was tolerable and no patients died during complete remission.
authors.affiliation: Department of Medicine, Fujita Health University School of Medicine, Aichi, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Ino
authors.forename: H
authors.initials: H
authors.lastname: Kojima
authors.forename: H
authors.initials: H
authors.lastname: Miyazaki
authors.forename: F
authors.initials: F
authors.lastname: Maruyama
authors.forename: R
authors.initials: R
authors.lastname: Sobue
authors.forename: M
authors.initials: M
authors.lastname: Okamoto
authors.forename: T
authors.initials: T
authors.lastname: Matsui
authors.forename: K
authors.initials: K
authors.lastname: Shimizu
authors.forename: K
authors.initials: K
authors.lastname: Ezaki
authors.forename: M
authors.initials: M
authors.lastname: Hirano
mesh_terms: D015250:Aclarubicin / Q000008:administration & dosage; D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage / Q000031:analogs & derivatives; D003630:Daunorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000401:mortality; D015993:Life Tables; D008297:Male; D015122:Mercaptopurine / Q000008:administration & dosage; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D011239:Prednisolone / Q000008:administration & dosage; D012074:Remission Induction; D015996:Survival Rate
chemical_list: D003561:Cytarabine; D005047:Etoposide; D015250:Aclarubicin; D011239:Prednisolone; D008942:Mitoxantrone; D015122:Mercaptopurine; D003630:Daunorubicin